Beijing, China, August 10 2023 – The National Medical Products Administration (NMPA) approved the registration application for the Hip Replacement Surgery Navigation and Positioning System "Lancet RobPath", developed by Hangzhou Lancet Robotics Co., Ltd.
Milestones for Lancet RobPath in THA (Total Hip Arthroplasty):
August 10, 2023 – Obtained NMPA Registration Certificate
December 20, 2022 – Obtained U.S. Food and Drug Administration (FDA) 510(K) Registration Certificate
March 30, 2022 – Approved by NMPA for Entry into Special Review Procedure for Innovative Medical Devices
Founded in 2018, Lancet Robotics is the world's sole medical robotic innovation company strategically focused on the four pivotal surgical domains: hip replacement, knee replacement, dental implantation, and vascular intervention. The company is dedicated to offering comprehensive solutions to hospitals, encompassing AI-assisted diagnosis, personalized surgical planning, surgical navigation robot systems, postoperative assessment, and more. Collaborating closely with Nanjing Drum Tower Hospital, the affiliated hospital of Nanjing University Medical School, Lancet Robotics has established a robust research and innovation platform that seamlessly integrates production, academia, research, and medical expertise.